| JoinClinicalTrials.com

Maine

• The Impact of Holding on Stress and Bonding in Mother-Infant Pairs During Therapeutic Hypothermia

  NCT03837717

  Conditions:   Hypoxic-Ischemic Encephalopathy;   Neonatal Encephalopathy
  Interventions:   Behavioral: Holding;   Other: Saliva collection;   Behavioral: No Holding
  Sponsor:   Maine Medical Center
  Recruiting
• Echocardiographic Risk Factors of Stroke in Patients With Atrial Fibrillation

  NCT03824509

  Conditions:   Atrial Fibrillation;   Stroke
  Intervention:   Other: Chart Review
  Sponsor:   Penobscot Bay Medical Center
  Enrolling by invitation
• Short Interval Resveratrol Trial in Cardiovascular Surgery

  NCT03762096

  Conditions:   Diabetes Mellitus, Type 2;   Coronary Artery Disease
  Interventions:   Dietary Supplement: Trans-resveratrol;   Dietary Supplement: Placebo
  Sponsors:   Maine Medical Center;   American Heart Association
  Recruiting
• Effects of Mediterranean Diet Intervention in Diabetic Heart Disease

  NCT03757845

  Conditions:   Diabetes Complications;   Cardiovascular Diseases
  Intervention:   Other: Mediterranean Diet
  Sponsor:   Maine Medical Center
  Recruiting
• Telemedicine to Improve Use of Therapeutic Hypothermia in Rural Settings

  NCT03706417

  Condition:   Neonatal Encephalopathy
  Intervention:   Diagnostic Test: Telemedicine consult
  Sponsor:   Maine Medical Center
  Recruiting
• Study of Peripherally Inserted Venous Catheters in Cystic Fibrosis Patients

  NCT03674216

  Condition:   Cystic Fibrosis
  Intervention:  
  Sponsors:   Jonathan B. Zuckerman;   Maine Medical Center;   Cystic Fibrosis Foundation
  Recruiting
• Neuroinflammatory Response and Headache Control in Patients After Subarachnoid Hemorrhage

  NCT03604276

  Conditions:   Subarachnoid Hemorrhage, Aneurysmal;   Headache;   Subarachnoid Hemorrhage
  Intervention:  
  Sponsor:   Maine Medical Center
  Recruiting
• Micronutrients as Adjunctive Treatment for Bipolar Disorder

  NCT03541031

  Condition:   Bipolar Disorder
  Interventions:   Dietary Supplement: Micronutrient & Fish oil;   Dietary Supplement: Olive oil & Safflower oil
  Sponsor:   Eastern Maine Medical Center
  Recruiting
• The Pain App Study: A Novel Shared Decision Making Tool for People With Chronic Pain

  NCT03425266

  Condition:   Chronic Pain
  Intervention:   Other: Interactive decision support tool
  Sponsors:   Shared Decision Making Resources;   University of New England;   Pfizer
  Enrolling by invitation
• Twice Daily Versus Twice Weekly Soak-and-Seal Baths in Pediatric Atopic Dermatitis

  NCT03397979

  Condition:   Atopic Dermatitis
  Intervention:   Behavioral: Infrequent versus Frequent Soaking Baths
  Sponsor:   Maine Medical Center
  Completed
• OMT to Improve Feeding After Hypothermia

  NCT03380013

  Conditions:   Neonatal Encephalopathy;   Feeding; Difficult, Newborn
  Intervention:   Procedure: Osteopathic Manipulative Treatment (OMT)
  Sponsor:   Maine Medical Center
  Completed
• Treatment of HFpEF With Nitrate Supplement

  NCT03289481

  Condition:   Heart Failure With Normal Ejection Fraction
  Intervention:   Dietary Supplement: Active lozenge
  Sponsors:   Penobscot Bay Medical Center;   HumanN
  Completed
• Study to Evaluate the Effectiveness of SGB in Preventing Post-op Atrial Fibrillation

  NCT03269383

  Condition:   Atrial Fibrillation
  Interventions:   Drug: Bupivacaine;   Other: Saline
  Sponsor:   Christopher Connors, MD
  Withdrawn
• Does Deep Neuromuscular Blockade Improve Operating Conditions During Total Hip Replacements?

  NCT03219294

  Condition:   Arthropathy of Hip
  Interventions:   Drug: Vecuronium 0.1 mg/kg;   Drug: Vecuronium 0.2mg/kg
  Sponsors:   Craig Curry;   Maine Medical Center;   Spectrum Medical Group Anesthesiology
  Completed
• Anticoagulation Therapy in the Very Old

  NCT03103763

  Condition:   Atrial Fibrillation
  Intervention:   Drug: Warfarin
  Sponsor:   Robert W. Stein, MD
  Active, not recruiting
• Holding, Stress, and Bonding During Therapeutic Hypothermia

  NCT03079284

  Condition:   Hypoxic-Ischemic Encephalopathy
  Intervention:   Other: Holding during cooling
  Sponsor:   Maine Medical Center
  Completed
• A Study of Tobacco Smoke and Children With Respiratory Illnesses

  NCT03062709

  Conditions:   Bronchiolitis;   Pneumonia;   Reactive Airway Disease;   Asthma;   Tobacco Smoking;   Tobacco Cessation;   Bronchopulmonary Dysplasia
  Interventions:   Behavioral: Breathe Easy Coalition written materials;   Behavioral: Maine Tobacco Helpline;   Diagnostic Test: Urine cotinine testing
  Sponsor:   Maine Medical Center
  Completed
• Delayed Rewarming for Neuroprotection in Infants Following Cardiopulmonary Bypass Surgery

  NCT03036072

  Condition:   Post-Op Complication
  Interventions:   Other: Strict normothermia;   Device: Delayed Rewarming
  Sponsor:   Maine Medical Center
  Completed
• A Comparison of Electromyographic Activity & Glenohumeral Motion

  NCT03001908

  Condition:   Orthopedic Disorder
  Interventions:   Other: glenohumeral mobilization-oscillation;   Other: glenohumeral mobilization-sustained
  Sponsor:   University of New England
  Completed
• Decreasing Rates of Intraurethral Catheterization Postoperatively in Spine Surgery

  NCT02919436

  Condition:   Post-operative Urinary Retention
  Interventions:   Drug: Tamsulosin;   Drug: Placebo
  Sponsor:   Maine Medical Center
  Recruiting
• Studies of Neuregulin/ERBB Signaling in Human Heart

  NCT02820233

  Conditions:   Heart Disease;   Vascular Disease;   Heart Failure
  Intervention:  
  Sponsors:   Douglas B. Sawyer;   Maine Medical Center
  Recruiting
• Neuregulin-1, Lipidomics, and Inflammation After Resuscitation From Cardiac Arrest

  NCT02664831

  Conditions:   Cardiac Arrest;   Inflammation;   Obesity
  Intervention:  
  Sponsor:   Maine Medical Center
  Recruiting
• Clinical Trial Comparing Tranexamic Acid (TXA) With Aquamantys Sealer in Total Knee Arthroplasty (TKA)

  NCT02374398

  Condition:   Blood Loss
  Interventions:   Drug: Tranexamic Acid;   Device: Aquamantys System;   Other: Control
  Sponsor:   Eastern Maine Medical Center
  Completed
• Comparing Femoral Nerve Catheters to Single Shot Femoral Nerve Blocks for Total Knee Replacement Surgery

  NCT02106481

  Condition:   Knee Osteoarthritis
  Interventions:   Drug: Femoral Nerve Catheters;   Drug: Single Shot Femoral Nerve Blocks
  Sponsor:   Eastern Maine Medical Center
  Completed
• Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)

  NCT01959945

  Condition:   Influenza
  Interventions:   Biological: Flublok® Quadrivalent Influenza Virus Vaccine;   Biological: Fluarix Quadrivalent® Influenza Virus Vaccine
  Sponsor:   Protein Sciences Corporation
  Completed
• Effect of Tyrosine Supplementation on Cognitive Performance and Mood During Military Stress

  NCT01913925

  Condition:   Reaction to Severe Stress, Unspecified
  Interventions:   Other: Tyrosine-Containing Food Bar;   Other: Placebo Bar
  Sponsor:   United States Army Research Institute of Environmental Medicine
  Completed
• Treatment of Neonatal Abstinence Syndrome

  NCT01723722

  Condition:   Neonatal Abstinence Syndrome
  Interventions:   Drug: Methadone;   Drug: Diluted Deodorized Tincture of Opium
  Sponsor:   Eastern Maine Medical Center
  Completed
• Hydroxycobalamin and Rural Emergency Medical Services Cyanide Exposure Patients: A Cost Analysis

  NCT01656616

  Condition:   Cyanide Poisoning
  Intervention:   Drug: Cyanide antidote administration
  Sponsor:   Maine Medical Center
  Withdrawn
• Psychosis: Early Detection, Intervention and Prevention

  NCT01597141

  Conditions:   Prodromal Schizophrenia;   Psychotic Disorders;   Severe Bipolar Disorder With Psychotic Features;   Severe Major Depression With Psychotic Features
  Interventions:   Behavioral: Family-aided Assertive Community Treatment;   Behavioral: Enhanced standard treatment
  Sponsors:   Maine Medical Center;   Columbia University;   Harvard University;   University of California, Irvine
  Completed
• The Effect of the Hemobag® Ultrafiltration System on Blood Conservation and Coagulation After Cardiopulmonary Bypass

  NCT01435304

  Condition:   Blood Coagulation Disorders
  Intervention:   Device: method of returning residual CPB blood ( Hemobag®)
  Sponsors:   Maine Medical Center;   Global Blood Resources, LLC
  Completed
• X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) Carrier Outlook Toward Reproduction Survey

  NCT01398813

  Conditions:   Hypohidrotic Ectodermal Dysplasia;   X-Linked Hypohidrotic Ectodermal Dysplasia
  Intervention:  
  Sponsor:   Edimer Pharmaceuticals
  Completed
• Vasopressin Effects on Human Social Communication

  NCT01327027

  Condition:   Healthy
  Interventions:   Drug: Vasopressin, Arginine, ADH;   Drug: Placebo; Sterile Saline
  Sponsors:   Bowdoin College;   Maine Medical Center;   National Institute of Mental Health (NIMH)
  Completed
• Testing Spread and Implementation of Novel Methicillin Resistant Staphylococcal Aureus (MRSA)-Reducing Practices

  NCT01255943

  Conditions:   Blood Stream Infections;   MRSA Infections
  Intervention:   Behavioral: healthcare staff processes for infection prevention
  Sponsors:   Maine Medical Center Research Institute;   Agency for Healthcare Research and Quality (AHRQ);   Indiana University School of Medicine
  Completed
• Prophylaxis to Reduce Postoperative Atrial Fibrillation in Cardiac Surgery

  NCT00953212

  Conditions:   Atrial Fibrillation;   Atrial Flutter
  Interventions:   Drug: beta blockers;   Drug: amiodarone;   Drug: ascorbic acid
  Sponsor:   Maine Medical Center
  Completed
• Family Exergaming: A Research Study Testing a Videogame Intervention to Increase Physical Activity for Families

  NCT00889122

  Condition:   Obesity
  Intervention:   Behavioral: Exergame (DDR)
  Sponsors:   Maine Medical Center;   Robert Wood Johnson Foundation
  Completed
• The Influence of Remote Ischemic Preconditioning on Acute Kidney Injury After Cardiac Surgery

  NCT00821522

  Conditions:   Acute Kidney Insufficiency;   Acute Renal Insufficiency;   Acute Kidney Injury;   Ischemic Preconditioning
  Intervention:   Procedure: Remote Ischemic Preconditioning
  Sponsor:   Maine Medical Center Research Institute
  Unknown status
• Deep Dive Randomized Control Trial

  NCT00793260

  Conditions:   Chronic Disease;   Arthritis;   Uterine Diseases;   Spinal Diseases;   Preventive Health Services
  Interventions:   Behavioral: Enhanced Support;   Behavioral: Usual-Support
  Sponsors:   Health Dialog;   Health Net California;   Highmark Blue Cross Blue Shield
  Completed
• Reduction of Mortality Prior to and During the First 90 Days of Dialysis Through a Renal Rehabilitation Program

  NCT00792454

  Conditions:   Chronic Kidney Disease;   End Stage Kidney Disease;   Cardiovascular Disease
  Intervention:   Behavioral: exercise training
  Sponsor:   Maine Medical Center
  Completed
• NOVA22007 0.05% and 0.1% Cyclosporine Versus Vehicle for the Treatment of Dry Eye

  NCT00739349

  Condition:   Dry Eye
  Interventions:   Drug: NOVA22007 ''Cyclosporine'';   Drug: vehicle/placebo
  Sponsor:   Santen SAS
  Completed
• Study of Osteopathic Manipulation in the Management of Angina

  NCT00708279

  Condition:   Angina Pectoris
  Intervention:   Procedure: Osteopathic manipulation
  Sponsors:   University of New England;   Osteopathic Heritage Foundations
  Completed
• AV Fistula Salvage in Advanced CKD Using Sodium Bicarbonate Prophylaxis

  NCT00621972

  Condition:   Acute Renal Failure
  Intervention:  
  Sponsor:   Maine Medical Center
  Withdrawn
• The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients

  NCT00600405

  Conditions:   Nephrolithiasis;   Ureteral Calculi
  Interventions:   Drug: tamsulosin;   Drug: Standard therapy with ibuprofen and oxycodone.
  Sponsors:   Maine Medical Center;   Maine Medical Center Mentored Research Committee
  Completed
• Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-007)

  NCT00548301

  Condition:   Dry Eye Syndromes
  Intervention:   Drug: cyclosporine
  Sponsor:   Sirion Therapeutics, Inc.
  Completed
• Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-005)

  NCT00502073

  Condition:   Dry Eye Syndromes
  Intervention:   Drug: cyclosporine
  Sponsor:   Sirion Therapeutics, Inc.
  Completed
• "Generation Fit and Exerlearning With In the Groove"

  NCT00424918

  Condition:   Obesity
  Intervention:   Behavioral: Physical Activity, reduced sedentary behavior
  Sponsor:   Maine Medical Center
  Completed
• Evaluation of an Investigational Multi-Purpose Disinfecting Solution for the Care of Silicone Hydrogel Soft Contact Lenses

  NCT00382902

  Condition:   Contact Lens Care
  Intervention:   Device: OptiFree Multi-Purpose Disinfecting Solution
  Sponsor:   Alcon Research
  Completed
• The Triglyceride Lowering Effect of an Omega-3 Fat (DHA) in Addition to Statin Therapy for Patients With CAD or Diabetes

  NCT00360217

  Conditions:   Hypertriglyceridemia (TG>200<500);   Hyperlipidemia;   Coronary Artery Disease;   Coronary Risk Equivalent;   Diabetes
  Intervention:   Drug: docosahexanoic acid (DHA)
  Sponsor:   Maine Center for Lipids and Cardiovascular Health
  Completed
• Blood Sample Donations to Study the Role of Genes in Pain

  NCT00341367

  Condition:   Pain
  Intervention:  
  Sponsor:   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
  Completed
• Lamotrigine in Treatment Resistant Depression in Adolescents

  NCT00284791

  Condition:   Adolescent Depression
  Interventions:   Drug: Lamotrigine (drug);   Drug: Fluoxetine (drug);   Drug: sertraline (drug)
  Sponsors:   Maine Medical Center;   GlaxoSmithKline
  Terminated
• Malignant Obstruction ZILVER Against Routine Therapy (MOZART I)

  NCT00196105

  Conditions:   Biliary Tract Neoplasms;   Pancreatic Neoplasms;   Jaundice, Obstructive
  Interventions:   Device: 6 mm Nitinol Zilver Stent;   Device: 10 mm Nitinol Zilver Stent;   Device: 10 mm Stainless Steel Wallstent
  Sponsor:   Cook Group Incorporated
  Completed
• The Effect of Thyroid Hormone Levels in Pregnant Women on the Intelligence Quotient (IQ) of Their Children

  NCT00147433

  Conditions:   Child Development Disorders;   Pregnancy;   Subclinical Hypothyroidism
  Intervention:  
  Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  Unknown status
• Prenatal Screening For Smith-Lemli-Opitz Syndrome

  NCT00070850

  Conditions:   Smith-Lemli-Opitz Syndrome;   Pregnancy
  Intervention:  
  Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  Completed
• Once Weekly Parathyroid Hormone for Osteoporosis

  NCT00065637

  Conditions:   Osteopenia;   Osteoporosis
  Interventions:   Drug: Teriparatide;   Drug: Placebo teriparatide
  Sponsors:   University of California, San Francisco;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
  Completed
• Addressing Mental Health Disparities in Refugee Children

  NCT03796065

  Condition:   Family Research
  Intervention:   Behavioral: FSI-R Treatment
  Sponsor:   Boston College
  Recruiting
• Online Mindfulness-based Tic Reduction (Phase Two)

  NCT03771235

  Conditions:   Tourette Syndrome;   Persistent Tic Disorder
  Interventions:   Behavioral: Mindfulness-based Intervention for Tics;   Behavioral: Tic Information and Coping Strategies
  Sponsors:   Bowdoin College;   Massachusetts General Hospital
  Recruiting
• Online Mindfulness-based Tic Reduction

  NCT03525626

  Conditions:   Tourette Syndrome;   Tic Disorders
  Intervention:   Behavioral: Online Mindfulness-based Tic Reduction
  Sponsors:   Bowdoin College;   Massachusetts General Hospital
  Active, not recruiting
• Safety and Efficacy of BRM421 for Dry Eye Syndrome

  NCT03066219

  Condition:   Dry Eye Syndrome
  Interventions:   Drug: BRM421;   Drug: Placebo
  Sponsor:   BRIM Biotechnology Inc.
  Completed
• Biomarkers of Iron Homeostasis and Responses to Cystic Fibrosis Pulmonary Exacerbation (CFPE) Treatment

  NCT02188758

  Condition:   Cystic Fibrosis
  Intervention:   Other: Adults - CFPE Treatment
  Sponsors:   Dartmouth-Hitchcock Medical Center;   Maine Medical Center
  Completed
• Does a Daily Iron Tablet Improve Anemia in Cystic Fibrosis

  NCT01755455

  Conditions:   Cystic Fibrosis;   Anemia, Iron-Deficiency
  Interventions:   Drug: Ferrous sulfate 325mg;   Drug: Placebo
  Sponsor:   Dartmouth-Hitchcock Medical Center
  Completed
• Balancing Act: Impact on Falls in Older Adults With Vision Impairment

  NCT02074488

  Condition:   Postural Balance
  Interventions:   Other: Balancing Act exercise curriculum;   Other: Informational Brochure
  Sponsors:   University of Maine;   University of New England;   National Institutes of Health (NIH);   National Institute on Aging (NIA)
  Completed
• Platelet Rich Plasma (PRP) in Total Knee Replacement

  NCT00826098

  Conditions:   Osteoarthritis;   Inflammatory Arthritis
  Intervention:   Biological: Platelet Rich Plasma
  Sponsor:   Exactech
  Completed
• Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis

  NCT00629941

  Condition:   Blepharitis
  Intervention:   Drug: AzaSite®
  Sponsor:   Merck Sharp & Dohme Corp.
  Completed
• Osteopathic Otitis Media Research Study

  NCT00520039

  Condition:   Otitis Media With Effusion
  Intervention:   Procedure: osteopathic manipulative medicine (OMM)
  Sponsors:   West Virginia School of Osteopathic Medicine;   University of New England;   American Academy of Osteopathy;   Osteopathic Research Center
  Completed
• Tocopherols and Alpha Lipoic Acid Treatment Chronic Kidney Disease (TALAT)

  NCT00308971

  Condition:   Chronic Kidney Disease
  Interventions:   Drug: Alpha, gamma, beta, and delta (mixed) tocopherols;   Drug: alpha lipoic acid;   Drug: placebo
  Sponsor:   Vanderbilt University
  Completed
• A Community Health Worker Program to Support Rural Older Adults

  NCT03843333

  Conditions:   Frail Elderly;   Cognitive Impairment;   Mobility Limitation;   Depressive Symptoms
  Interventions:   Behavioral: Tai Ji Quan: Moving for Better Balance;   Behavioral: Behavioral Activation;   Other: Resource Navigation;   Other: Enhanced Usual Care
  Sponsors:   University of Vermont;   Central Vermont Medical Center;   Dartmouth College;   Dartmouth-Hitchcock Medical Center;   Maine Medical Center;   MaineGeneral Health;   Maine-Dartmouth Family Medicine Residency;   Dartmouth SYNERGY Clinical and Translational Science Institute;   Northern New England Clinical and Translational Research Network
  Recruiting
• Multimedia Training for Family Caregivers in Use of Touch and Massage in Supportive Cancer Care

  NCT00632398

  Condition:   Cancer
  Interventions:   Behavioral: Attention control (reading);   Behavioral: Touch, Caring and Cancer DVD program
  Sponsors:   Collinge and Associates, Inc.;   National Cancer Institute (NCI)
  Completed
• Redesigning Cardiac Surgery to Reduce Neurologic Injury

  NCT00432536

  Conditions:   Cardiovascular Disease;   Surgery
  Intervention:   Other: Quality improvement intervention
  Sponsors:   Dartmouth-Hitchcock Medical Center;   Maine Medical Center;   Catholic Medical Center;   Somanetics Corporation;   LivaNova;   Maquet Cardiovascular;   Northern New England Cardiovascular Disease Study Group;   Luna Innovations;   Agency for Healthcare Research and Quality (AHRQ)
  Completed
• Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome

  NCT00198536

  Condition:   Dry Eye Syndromes
  Interventions:   Drug: Ecabet 2.83%;   Drug: Ecabet 3.70%;   Drug: Vehicle
  Sponsor:   Bausch & Lomb Incorporated
  Completed
• Indomethacin Germinal Matrix Hemorrhage/Intraventricular Hemorrhage (GMH/IVH) Prevention Trial

  NCT00033917

  Conditions:   Intraventricular Hemorrhage (IVH);   Bleeding in the Brain;   Prematurity;   Very Low Birth Weight Infants
  Interventions:   Drug: indomethacin;   Drug: placebo
  Sponsor:   Yale University
  Completed
• Study of TOP1630 for Dry Eye Syndrome

  NCT03833388

  Condition:   Dry Eye Syndrome
  Interventions:   Drug: TOP1630 0.1% Ophthalmic Solution TID OU;   Drug: Placebo to TOP1630 0.1% Ophthalmic Solution TID OU
  Sponsor:   Topivert Pharma Ltd
  Recruiting
• Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia

  NCT00477594

  Conditions:   Lipid Metabolism, Inborn Errors;   Hypercholesterolemia, Autosomal Dominant;   Hyperlipidemias;   Metabolic Diseases;   Hyperlipoproteinemia Type II;   Metabolism, Inborn Errors;   Genetic Diseases, Inborn;   Infant, Newborn, Diseases;   Metabolic Disorder;   Congenital Abnormalities;   Hypercholesterolemia;   Hyperlipoproteinemias;   Dyslipidemias;   Lipid Metabolism Disorders
  Intervention:   Drug: mipomersen sodium
  Sponsors:   Kastle Therapeutics, LLC;   Ionis Pharmaceuticals, Inc.
  Completed
• Treatment Decisions for Multi-vessel CAD

  NCT02611050

  Condition:   Coronary Artery Disease
  Interventions:   Behavioral: The Multi-vessel Coronary Artery Disease Option Grid;   Behavioral: Usual Care
  Sponsor:   Dartmouth-Hitchcock Medical Center
  Terminated
• Amantadine to Speed Awakening After Cardiac Arrest

  NCT02486211

  Conditions:   Coma;   Heart Arrest;   Anoxia
  Interventions:   Drug: Amantadine;   Drug: Placebo
  Sponsors:   Jon Rittenberger, MD;   American Heart Association
  Completed
• HOBSCOTCH Phase II

  NCT02394509

  Condition:   Epilepsy
  Intervention:   Behavioral: Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH)
  Sponsors:   Dartmouth-Hitchcock Medical Center;   Centers for Disease Control and Prevention
  Active, not recruiting
• Pilot Study for Young Women's Intervention

  NCT01647594

  Condition:   Breast Cancer
  Interventions:   Behavioral: YWI;   Behavioral: Physical Activity
  Sponsors:   Dana-Farber Cancer Institute;   American Society of Clinical Oncology
  Completed
• Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients

  NCT02625935

  Condition:   Breast Cancer
  Intervention:  
  Sponsor:   NanoString Technologies, Inc.
  Completed
• CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)

  NCT02617667

  Condition:   Dry Eye Syndromes
  Interventions:   Drug: Cyclosporine A;   Drug: Placebo
  Sponsor:   Novaliq GmbH
  Completed
• Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma

  NCT01234766

  Condition:   Lymphoma, Follicular
  Interventions:   Drug: Bendamustine;   Drug: Rituximab;   Radiation: Y-90 ibritumomab
  Sponsors:   Dartmouth-Hitchcock Medical Center;   Cephalon;   Spectrum Pharmaceuticals, Inc
  Active, not recruiting
• Decision Aid for Renal Therapy

  NCT03522740

  Conditions:   Chronic Kidney Diseases;   Kidney Failure, Chronic
  Intervention:   Other: Decision Aid for Renal Therapy
  Sponsors:   Tufts University;   Patient-Centered Outcomes Research Institute
  Recruiting
• Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia

  NCT01968720

  Conditions:   Hyperlipidemias;   Hypertriglyceridemia;   Dyslipidemias;   Lipid Metabolism Disorders;   Metabolic Diseases
  Interventions:   Drug: CAT-2003;   Drug: Placebo
  Sponsor:   Catabasis Pharmaceuticals
  Completed
• Buprenorphine/Naloxone - Facilitated Rehabilitation for Opioid Dependent Adolescents - 1

  NCT00078130

  Condition:   Opioid-Related Disorders
  Intervention:   Drug: Buprenorphine/naloxone
  Sponsor:   University of Pennsylvania
  Completed
• PaTH Study: Parathyroid Hormone and Alendronate for Osteoporosis

  NCT00005005

  Condition:   Osteoporosis
  Interventions:   Drug: PTH;   Drug: Alendronate
  Sponsors:   Dennis Black;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
  Completed
• Early Detection of Ovarian Cancer: GC/FT-ICR Mass Spectrometry and Canine Olfaction

  NCT00757952

  Condition:   Ovarian Cancer
  Interventions:   Other: Fourier transform ion cyclotron resonance mass spectrometry;   Other: chromatography;   Other: diagnostic laboratory biomarker analysis;   Other: questionnaire administration
  Sponsor:   Pine Street Foundation
  Completed
• Promoting Informed Decisions About Cancer Screening in Older Adults

  NCT03959696

  Condition:   Colorectal Cancer Screening
  Interventions:   Behavioral: Notification;   Behavioral: Training
  Sponsors:   Massachusetts General Hospital;   Maine Medical Center;   Brigham and Women's Hospital;   Newton-Wellesley Hospital;   North Shore Medical Center
  Enrolling by invitation
• Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery

  NCT02389023

  Conditions:   Peripheral Artery Disease;   Critical Limb Ischemia;   Claudication
  Interventions:   Other: standard gauze dressing;   Other: Prevena Incision Management system
  Sponsors:   University of Vermont Medical Center;   KCI USA, Inc.;   Maine Medical Center;   Brigham and Women's Hospital;   Beth Israel Deaconess Medical Center;   Dartmouth-Hitchcock Medical Center
  Recruiting
• A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye

  NCT01960010

  Condition:   Dry Eye Syndromes
  Interventions:   Drug: MIM-D3 Ophthalmic Solution;   Drug: Vehicle
  Sponsor:   Mimetogen Pharmaceuticals USA, Inc.
  Completed
• Targeting Inflammation Using Salsalate in CardioVascular Disease

  NCT00624923

  Conditions:   Coronary Artery Disease;   Overweight
  Interventions:   Drug: Salsalate;   Drug: Placebo
  Sponsors:   Joslin Diabetes Center;   Beth Israel Deaconess Medical Center;   Tufts Medical Center;   National Heart, Lung, and Blood Institute (NHLBI)
  Completed
• Safety and Efficacy Study of EGP-437 (Dexamethasone Phosphate Formulated for Ocular Iontophoresis) to Treat Dry Eye

  NCT01129856

  Condition:   Dry Eye
  Interventions:   Drug: Dexamethasone phosphate ophthalmic solution;   Drug: Sodium citrate buffer solution
  Sponsor:   Eyegate Pharmaceuticals, Inc.
  Completed
• Dose-escalating Safety Study in Subjects on Stable Statin Therapy

  NCT00231569

  Condition:   Hypercholesterolemia
  Intervention:   Drug: ISIS 301012 or Placebo
  Sponsors:   Kastle Therapeutics, LLC;   Ionis Pharmaceuticals, Inc.
  Completed
• Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia

  NCT02250105

  Condition:   Hypertriglyceridemia
  Interventions:   Drug: ARI-3037MO;   Drug: Placebo
  Sponsors:   Arisaph Pharmaceuticals Inc;   Baim Institute for Clinical Research
  Completed
• A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE)

  NCT00926185

  Condition:   Dry Eye
  Interventions:   Drug: Lifitegrast;   Drug: Placebo
  Sponsor:   Shire
  Completed
• RCT of the Restorative Practices Intervention

  NCT02155296

  Conditions:   Intervention Schools (Schools Receiving RPI);   Control Schools (Schools Not Receiving RPI)
  Intervention:   Behavioral: Restorative Practices Intervention
  Sponsors:   RAND;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  Completed
• Video Support Program For Families With a Parent Newly Diagnosed With Cancer

  NCT00020553

  Condition:   Psychosocial Effects of Cancer and Its Treatment
  Intervention:   Procedure: psychosocial assessment and care
  Sponsors:   Inflexxion, Inc.;   National Cancer Institute (NCI)
  Unknown status
• Long-Term Outcomes for Lumbar Spinal Stenosis Patients Treated With X STOP®

  NCT00534092

  Condition:   Lumbar Spinal Stenosis
  Intervention:   Device: X STOP® Interspinous Process Decompression System
  Sponsor:   Medtronic Spine LLC
  Completed
• Evaluation of Efficacy of Ophthalmic Solution in Induced Acute Allergic Conjunctivitis

  NCT00241319

  Condition:   Allergic Conjunctivitis
  Intervention:   Drug: R89674 (generic name not yet established)
  Sponsor:   Vistakon Pharmaceuticals
  Completed
• An Evaluation of Innerview™, a Web-based Tool to Support the Integration of Mental Health in the Primary Care Setting

  NCT02025647

  Condition:   Mental Health
  Intervention:  
  Sponsor:   Pearson/Clinical Assessment
  Completed
• Therapy for Pediatric Hodgkin Lymphoma

  NCT00145600

  Condition:   Hodgkin Lymphoma
  Interventions:   Drug: 12 Week Stanford V Chemotherapy;   Drug: 4 cycles of VAMP chemotherapy;   Drug: 2 alternating cycles of VAMP/COP chemotherapy;   Drug: 3 alternating cycles of VAMP/COP chemotherapy
  Sponsor:   St. Jude Children's Research Hospital
  Active, not recruiting
• Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye

  NCT01027013

  Conditions:   Dry Eye Syndromes;   Keratoconjunctivitis Sicca
  Interventions:   Drug: rebamipide 2% ophthalmic suspension;   Drug: placebo eye drops
  Sponsors:   Acucela Inc.;   Otsuka Pharmaceutical Co., Ltd.
  Completed
• Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

  NCT03768414

  Conditions:   Stage III Distal Bile Duct Cancer AJCC v8;   Stage III Gallbladder Cancer AJCC v8;   Stage III Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIA Distal Bile Duct Cancer AJCC v8;   Stage IIIA Gallbladder Cancer AJCC v8;   Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIB Distal Bile Duct Cancer AJCC v8;   Stage IIIB Gallbladder Cancer AJCC v8;   Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IV Distal Bile Duct Cancer AJCC v8;   Stage IV Gallbladder Cancer AJCC v8;   Stage IV Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IVA Gallbladder Cancer AJCC v8;   Stage IVB Gallbladder Cancer AJCC v8;   Unresectable Extrahepatic Bile Duct Carcinoma;   Unresectable Gallbladder Carcinoma;   Unresectable Intrahepatic Cholangiocarcinoma
  Interventions:   Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Drug: Nab-paclitaxel
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

  NCT03851445

  Condition:   Previously Treated Non-Small Cell Lung Cancer
  Intervention:   Drug: Screening Platform
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer

  NCT03377556

  Conditions:   ATM Gene Mutation;   ATR Gene Mutation;   BARD1 Gene Mutation;   BRCA1 Gene Mutation;   BRCA2 Gene Mutation;   BRIP1 Gene Mutation;   CHEK1 Gene Mutation;   CHEK2 Gene Mutation;   FANCA Gene Mutation;   FANCC Gene Mutation;   FANCD2 Gene Mutation;   FANCF Gene Mutation;   FANCM Gene Mutation;   NBN Gene Mutation;   PALB2 Gene Mutation;   RAD51 Gene Mutation;   RAD51B Gene Mutation;   RAD54L Gene Mutation;   Recurrent Squamous Cell Lung Carcinoma;   RPA1 Gene Mutation;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Talazoparib
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer

  NCT03244384

  Conditions:   Stage II Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
  Interventions:   Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer

  NCT03382561

  Conditions:   Extensive Stage Lung Small Cell Carcinoma;   Recurrent Lung Small Cell Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

  NCT03055013

  Conditions:   Metastatic Malignant Neoplasm in Lymph Node;   Metastatic Malignant Neoplasm in the Adrenal Gland;   Metastatic Malignant Neoplasm in the Lung;   Metastatic Malignant Neoplasm in the Pancreas;   Metastatic Malignant Neoplasm in the Skin;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Renal Cell Carcinoma;   Oligometastasis;   Sarcomatoid Renal Cell Carcinoma;   Stage II Renal Cell Cancer AJCC v7;   Stage III Renal Cell Cancer AJCC v7;   Unclassified Renal Cell Carcinoma
  Interventions:   Procedure: Conventional Surgery;   Biological: Nivolumab;   Other: Patient Observation;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer

  NCT02954874

  Conditions:   Estrogen Receptor Negative;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Progesterone Receptor Negative;   Stage 0 Breast Cancer AJCC v6 and v7;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Triple-Negative Breast Carcinoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Patient Observation;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

  NCT02927249

  Condition:   Node Positive HER2 Negative Breast Cancer
  Interventions:   Other: Placebo;   Drug: Aspirin
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   United States Department of Defense;   Bayer;   Canadian Cancer Trials Group
  Recruiting
• Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  NCT03092674

  Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts-2;   Untreated Adult Acute Myeloid Leukemia
  Interventions:   Drug: Azacitidine;   Drug: Cytarabine;   Drug: Decitabine;   Other: Laboratory Biomarker Analysis;   Drug: Midostaurin;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Suspended
• Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

  NCT02912559

  Conditions:   Colon Adenocarcinoma;   DNA Repair Disorder;   Lynch Syndrome;   Stage III Colon Cancer AJCC v7;   Stage IIIA Colon Cancer AJCC v7;   Stage IIIB Colon Cancer AJCC v7;   Stage IIIC Colon Cancer AJCC v7
  Interventions:   Drug: Atezolizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826

  Condition:   Breast Carcinoma
  Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
  Recruiting
• Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

  NCT02785952

  Conditions:   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
  Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)

  NCT02595944

  Conditions:   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
  Intervention:   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer

  NCT02997228

  Conditions:   Colorectal Adenocarcinoma;   Mismatch Repair Deficiency;   Stage IV Colorectal Cancer AJCC v7;   Stage IVA Colorectal Cancer AJCC v7;   Stage IVB Colorectal Cancer AJCC v7
  Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Drug: Fluorouracil;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

  NCT02465060

  Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
  Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab Emtansine;   Drug: Vismodegib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer

  NCT03373760

  Conditions:   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
  Interventions:   Biological: Durvalumab;   Other: Laboratory Biomarker Analysis;   Biological: Tremelimumab
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

  NCT02201992

  Conditions:   ALK Gene Rearrangement;   ALK Gene Translocation;   ALK Positive;   Stage IB Non-Small Cell Lung Carcinoma AJCC v7;   Stage II Non-Small Cell Lung Cancer AJCC v7;   Stage IIA Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Laboratory Biomarker Analysis
  Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
  Recruiting
• Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

  NCT02194738

  Conditions:   Lung Adenocarcinoma;   Lung Large Cell Carcinoma;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IB Lung Squamous Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage II Lung Squamous Cell Carcinoma AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIA Lung Squamous Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Squamous Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7;   Stage IIIA Lung Squamous Cell Carcinoma AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Erlotinib Hydrochloride;   Biological: Nivolumab;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

  NCT02193282

  Conditions:   ALK Gene Rearrangement;   EGFR Exon 19 Deletion Mutation;   EGFR NP_005219.2:p.L858R;   Stage IB Lung Non-Small Cell Carcinoma AJCC v7;   Stage II Lung Non-Small Cell Cancer AJCC v7;   Stage IIA Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIB Lung Non-Small Cell Carcinoma AJCC v7;   Stage IIIA Lung Non-Small Cell Cancer AJCC v7
  Interventions:   Other: Clinical Observation;   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

  NCT02196181

  Conditions:   BRAF V600E Mutation Present;   BRAF V600K Mutation Present;   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Melanoma
  Interventions:   Drug: Dabrafenib;   Drug: Trametinib
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

  NCT02154490

  Conditions:   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
  Interventions:   Drug: Docetaxel;   Biological: Durvalumab;   Drug: Erlotinib Hydrochloride;   Drug: FGFR Inhibitor AZD4547;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Palbociclib;   Other: Pharmacological Study;   Biological: Rilotumumab;   Drug: Talazoparib;   Drug: Taselisib;   Biological: Tremelimumab
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery

  NCT03033576

  Conditions:   Stage III Cutaneous Melanoma AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Melanoma
  Interventions:   Biological: Ipilimumab;   Biological: Nivolumab
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

  NCT02032823

  Condition:   Breast Cancer
  Interventions:   Drug: Olaparib;   Drug: Placebo
  Sponsors:   AstraZeneca;   Breast International Group;   Frontier Science & Technology Research Foundation, Inc.;   NRG Oncology;   Myriad Genetic Laboratories, Inc.;   Br.E.A.S.T. -Data Center & Operational Office Institut Jules Bordet;   Merck Sharp & Dohme Corp.
  Active, not recruiting
• Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

  NCT02965378

  Conditions:   FGFR1 Gene Amplification;   FGFR1 Gene Mutation;   FGFR2 Gene Amplification;   FGFR2 Gene Mutation;   FGFR3 Gene Amplification;   FGFR3 Gene Mutation;   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
  Interventions:   Drug: Docetaxel;   Drug: FGFR Inhibitor AZD4547;   Other: Laboratory Biomarker Analysis
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

  NCT02926638

  Conditions:   MET Positive;   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
  Interventions:   Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Biological: Rilotumumab
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

  NCT02785939

  Conditions:   CCND1 Gene Amplification;   CCND2 Gene Amplification;   CCND3 Gene Amplification;   CDK4 Gene Amplification;   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
  Interventions:   Drug: Docetaxel;   Other: Laboratory Biomarker Analysis;   Drug: Palbociclib
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

  NCT02785913

  Conditions:   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Taselisib
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

  NCT02766335

  Conditions:   Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma AJCC v7
  Interventions:   Drug: Docetaxel;   Biological: Durvalumab;   Other: Laboratory Biomarker Analysis
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

  NCT01674140

  Condition:   Breast Cancer
  Interventions:   Drug: anastrozole;   Drug: everolimus;   Drug: exemestane;   Drug: goserelin acetate;   Drug: letrozole;   Drug: leuprolide acetate;   Drug: tamoxifen citrate;   Other: placebo
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

  NCT02488967

  Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
  Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

  NCT01863550

  Condition:   Plasma Cell Myeloma
  Interventions:   Drug: Bortezomib;   Drug: Carfilzomib;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Other: Quality-of-Life Assessment
  Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
  Recruiting
• Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

  NCT02115282

  Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Drug: Entinostat;   Drug: Exemestane;   Drug: Goserelin Acetate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Placebo;   Other: Quality-of-Life Assessment
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Cardiovascular Inflammation Reduction Trial

  NCT01594333

  Condition:   Cardiovascular Disease
  Interventions:   Drug: Methotrexate;   Drug: Placebo
  Sponsors:   Brigham and Women's Hospital;   National Heart, Lung, and Blood Institute (NHLBI)
  Active, not recruiting
• A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors

  NCT02019264

  Conditions:   Cardiovascular Disease;   High Cardiovascular Risk;   Obesity;   Overweight;   Type 2 Diabetes
  Interventions:   Drug: APD356-Lorcaserin hydrochloride;   Drug: Placebo
  Sponsors:   Eisai Inc.;   Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization
  Completed
• Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

  NCT01275677

  Conditions:   Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Positive;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7
  Interventions:   Drug: Cyclophosphamide;   Drug: Docetaxel;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Biological: Trastuzumab
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

  NCT01901094

  Conditions:   Stage II Breast Cancer;   Stage IIIA Breast Cancer
  Interventions:   Procedure: Axillary Lymph Node Dissection (ALND);   Radiation: Nodal Radiation Therapy;   Radiation: Axillary Radiation Therapy
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Canadian Cancer Trials Group
  Recruiting
• Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

  NCT01886872

  Conditions:   CD19 Positive;   CD20 Positive;   CD5 Positive;   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
  Interventions:   Drug: Bendamustine Hydrochloride;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Biological: Rituximab
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

  NCT03367702

  Condition:   Stage II Prostate Adenocarcinoma
  Interventions:   Radiation: Intensity-Modulated Radiation Therapy (IMRT);   Radiation: Stereotactic Body Radiation Therapy (SBRT)
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

  NCT01274338

  Conditions:   Melanoma of Unknown Primary;   Recurrent Melanoma;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7
  Interventions:   Biological: Ipilimumab;   Other: Quality-of-Life Assessment;   Biological: Recombinant Interferon Alfa-2b
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

  NCT01272037

  Conditions:   Ductal Breast Carcinoma In Situ;   Estrogen Receptor Positive;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Multicentric Breast Carcinoma;   Multifocal Breast Carcinoma;   Progesterone Receptor Positive;   Synchronous Bilateral Breast Carcinoma
  Interventions:   Drug: Anastrozole;   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Quality-of-Life Assessment;   Drug: Systemic Chemotherapy;   Drug: Tamoxifen Citrate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

  NCT01663402

  Condition:   Atherosclerotic Cardiovascular Disease
  Interventions:   Drug: Alirocumab;   Drug: Placebo;   Drug: LMT
  Sponsors:   Sanofi;   Regeneron Pharmaceuticals
  Completed
• Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer

  NCT01547741

  Condition:   Breast Cancer
  Interventions:   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Docetaxel;   Drug: Paclitaxel
  Sponsors:   NSABP Foundation Inc;   National Cancer Institute (NCI)
  Active, not recruiting
• A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

  NCT03009981

  Condition:   Prostate Cancer
  Interventions:   Drug: Apalutamide;   Drug: LHRH Analogue;   Drug: Abiraterone Acetate;   Drug: Prednisone
  Sponsors:   Alliance Foundation Trials, LLC.;   Janssen Research & Development, LLC
  Recruiting
• Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction

  NCT02929329

  Condition:   Heart Failure
  Interventions:   Drug: Omecamtiv Mecarbil;   Drug: Placebo
  Sponsors:   Amgen;   Cytokinetics;   Servier
  Recruiting
• FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

  NCT02890355

  Conditions:   Metastatic Pancreatic Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage IV Pancreatic Cancer AJCC v6 and v7
  Interventions:   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Veliparib
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

  NCT02595905

  Conditions:   Breast Carcinoma Metastatic in the Brain;   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer AJCC v6 and v7;   Triple-Negative Breast Carcinoma
  Interventions:   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Drug: Veliparib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

  NCT02506153

  Conditions:   Metastatic Non-Cutaneous Melanoma;   Non-Cutaneous Melanoma;   Recurrent Cutaneous Melanoma;   Recurrent Non-Cutaneous Melanoma;   Stage III Cutaneous Melanoma AJCC v7;   Stage III Mucosal Melanoma of the Head and Neck AJCC v7;   Stage IIIA Cutaneous Melanoma AJCC v7;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Stage IVA Mucosal Melanoma of the Head and Neck AJCC v7;   Stage IVB Mucosal Melanoma of the Head and Neck AJCC v7;   Stage IVC Mucosal Melanoma of the Head and Neck AJCC v7
  Interventions:   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Biological: Recombinant Interferon Alfa-2b
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy

  NCT02445391

  Conditions:   Estrogen Receptor Negative;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Progesterone Receptor Negative;   Stage II Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage III Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
  Interventions:   Drug: Capecitabine;   Drug: Carboplatin;   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Procedure: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   ECOG-ACRIN Cancer Research Group;   National Cancer Institute (NCI)
  Recruiting
• S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

  NCT02438722

  Conditions:   Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer
  Interventions:   Drug: Afatinib Dimaleate;   Biological: Cetuximab;   Other: Laboratory Biomarker Analysis
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

  NCT01150045

  Condition:   Colorectal Cancer
  Interventions:   Drug: celecoxib;   Drug: 5-fluorouracil;   Other: placebo;   Drug: oxaliplatin;   Drug: leucovorin
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Active, not recruiting
• S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

  NCT01120249

  Condition:   Kidney Cancer
  Interventions:   Drug: everolimus;   Other: placebo
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer

  NCT02364557

  Conditions:   Dyspnea;   Fatigue;   Nausea and Vomiting;   Pain;   Stage IV Breast Cancer
  Interventions:   Radiation: Stereotactic Radiosurgery;   Procedure: Therapeutic Conventional Surgery;   Other: Laboratory Biomarker Analysis
  Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
  Recruiting
• Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

  NCT02152982

  Conditions:   Glioblastoma;   Gliosarcoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment;   Drug: Temozolomide;   Drug: Veliparib
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Evaluation of Loratadine for Prevention of Pegfilgrastim-Induced Pain

  NCT01311336

  Condition:   Pegfilgrastim-induced Back and Leg Pain
  Interventions:   Drug: Loratadine;   Drug: placebo
  Sponsors:   University of Vermont;   Cancer and Leukemia Group B
  Unknown status
• Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

  NCT00310180

  Conditions:   Breast Adenocarcinoma;   Estrogen Receptor and/or Progesterone Receptor Positive;   HER2/Neu Negative;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage IIIB Breast Cancer AJCC v7
  Interventions:   Drug: Anastrozole;   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Drug: Tamoxifen Citrate
  Sponsors:   National Cancer Institute (NCI);   American College of Surgeons;   Cancer and Leukemia Group B;   NSABP Foundation Inc;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group;   Southwest Oncology Group
  Active, not recruiting
• Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

  NCT00324805

  Conditions:   Stage IB Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIA Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIB Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIIA Non-Small Cell Lung Cancer AJCC v7
  Interventions:   Biological: Bevacizumab;   Drug: Cisplatin;   Drug: Docetaxel;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Pemetrexed Disodium;   Other: Questionnaire Administration;   Drug: Vinorelbine Tartrate
  Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group;   Southwest Oncology Group
  Active, not recruiting
• Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT02048813

  Conditions:   Anemia;   Chronic Lymphocytic Leukemia;   Fatigue;   Fever, Sweat, and Hot Flashes;   Hepatomegaly;   Lymphadenopathy;   Lymphocytosis;   Small Lymphocytic Lymphoma;   Splenomegaly;   Thrombocytopenia;   Weight Change
  Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Biological: Rituximab
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma

  NCT02004275

  Condition:   Multiple Myeloma in Relapse
  Interventions:   Drug: pomalidomide;   Drug: ixazomib;   Drug: dexamethasone
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Celgene Corporation;   Millennium Pharmaceuticals, Inc.
  Recruiting
• Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery

  NCT00326898

  Conditions:   Clear Cell Renal Cell Carcinoma;   Stage I Renal Cell Cancer AJCC v6 and v7;   Stage II Renal Cell Cancer AJCC v7;   Stage III Renal Cell Cancer AJCC v7
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment;   Drug: Sorafenib Tosylate;   Drug: Sunitinib Malate
  Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   Southwest Oncology Group
  Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

  NCT01975389

  Condition:   Cardiovascular Disease
  Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
  Sponsor:   Pfizer
  Terminated
• Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

  NCT01953588

  Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Lobular Breast Carcinoma;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
  Interventions:   Drug: fulvestrant;   Drug: anastrozole
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

  NCT01950390

  Conditions:   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7;   Unresectable Melanoma
  Interventions:   Biological: Bevacizumab;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

  NCT01949337

  Conditions:   Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
  Interventions:   Drug: enzalutamide;   Drug: abiraterone;   Drug: prednisone
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Astellas Pharma US, Inc.;   Medivation, Inc.;   Biologics, Inc.
  Active, not recruiting
• Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

  NCT00769379

  Conditions:   Ductal Breast Carcinoma In Situ;   HER2/Neu Positive
  Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Trastuzumab;   Radiation: Whole Breast Irradiation
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma

  NCT01903811

  Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
  Interventions:   Drug: Carfilzomib;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Breast Cancer Registry for Participants With Breast Cancer or Characteristics of Hereditary Breast Cancer

  NCT00666731

  Conditions:   Breast Cancer;   Precancerous Condition
  Interventions:   Other: medical chart review;   Other: questionnaire administration;   Other: study of socioeconomic and demographic variables;   Procedure: Excess human biological tissue;   Procedure: quality-of-life assessment
  Sponsors:   University of Nebraska;   National Cancer Institute (NCI)
  Completed
• A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome

  NCT00658515

  Condition:   Coronary Heart Disease
  Interventions:   Drug: Dalcetrapib (RO4607381);   Drug: Evidence-based medical care for Acute Coronary Syndrome;   Drug: Placebo
  Sponsor:   Hoffmann-La Roche
  Completed
• Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

  NCT01764633

  Condition:   Dyslipidemia
  Interventions:   Biological: Evolocumab;   Drug: Placebo
  Sponsor:   Amgen
  Completed
• Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

  NCT01730534

  Conditions:   Diabetes Mellitus, Non-Insulin-Dependent;   High Risk for Cardiovascular Event
  Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Placebo tablet
  Sponsors:   AstraZeneca;   Bristol-Myers Squibb;   The TIMI Study Group;   Hadassah Medical Organization
  Completed
• Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer

  NCT01642251

  Conditions:   Extensive Stage Small Cell Lung Carcinoma;   Large Cell Lung Carcinoma;   Neuroendocrine Carcinoma;   Small Cell Carcinoma;   Stage IV Non-Small Cell Lung Cancer AJCC v7
  Interventions:   Drug: Cisplatin;   Drug: Etoposide;   Drug: Veliparib;   Drug: Placebo
  Sponsor:   National Cancer Institute (NCI)
  Completed
• S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy

  NCT01598298

  Conditions:   Breast Cancer;   Musculoskeletal Complications;   Pain
  Interventions:   Drug: duloxetine hydrochloride;   Other: placebo
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Completed
• Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration

  NCT01577381

  Condition:   Age-Related Maculopathy
  Interventions:   Biological: RN6G;   Biological: Placebo
  Sponsor:   Pfizer
  Terminated
• Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

  NCT01575548

  Conditions:   Clear Cell Renal Cell Carcinoma;   No Evidence of Disease;   Stage IV Renal Cell Cancer AJCC v7
  Interventions:   Drug: Pazopanib Hydrochloride;   Other: Pharmacological Study;   Other: Placebo;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

  NCT00433511

  Conditions:   Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Negative;   Male Breast Carcinoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
  Interventions:   Biological: Bevacizumab;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Placebo;   Other: Quality-of-Life Assessment
  Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   Eastern Cooperative Oncology Group;   North Central Cancer Treatment Group
  Active, not recruiting
• Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

  NCT01225562

  Conditions:   Myocardial Infarction;   Cardiovascular Death;   Atherothrombosis;   Stroke
  Interventions:   Drug: Ticagrelor 90 mg;   Drug: Ticagrelor 60 mg;   Drug: Ticagrelor Placebo
  Sponsor:   AstraZeneca
  Completed
• JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events

  NCT00239681

  Condition:   Elevated High-sensitivity C-Reactive Protein (hsCRP)
  Interventions:   Drug: Rosuvastatin;   Other: Placebo
  Sponsor:   AstraZeneca
  Terminated
• Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

  NCT01169337

  Conditions:   Light Chain Deposition Disease;   Smoldering Plasma Cell Myeloma
  Interventions:   Other: Clinical Observation;   Drug: Lenalidomide;   Other: Quality-of-Life Assessment
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung

  NCT01154140

  Condition:   Non Squamous Lung Cancer
  Intervention:   Drug: treatment
  Sponsor:   Pfizer
  Completed
• JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab

  NCT01070836

  Condition:   Relapsing Multiple Sclerosis
  Intervention:   Drug: natalizumab
  Sponsor:   Biogen
  Completed
• Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

  NCT00878709

  Condition:   Breast Cancer
  Interventions:   Drug: neratinib;   Other: placebo
  Sponsor:   Puma Biotechnology, Inc.
  Active, not recruiting
• Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer

  NCT00785291

  Conditions:   Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Negative;   HER2/Neu Positive;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIC Breast Cancer AJCC v6;   Stage IV Breast Cancer AJCC v6 and v7
  Interventions:   Biological: Bevacizumab;   Drug: Ixabepilone;   Other: Laboratory Biomarker Analysis;   Drug: Nab-paclitaxel;   Drug: Paclitaxel;   Other: Questionnaire Administration
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms

  NCT00443274

  Condition:   Breast Implant
  Interventions:   Other: NBIR Placeholder;   Device: 410 Arm;   Device: BIFs
  Sponsor:   Allergan
  Recruiting
• Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation

  NCT00402363

  Condition:   Fibrillation, Atrial
  Interventions:   Drug: omega-3-acid ethyl esters;   Drug: Placebo
  Sponsor:   GlaxoSmithKline
  Completed
• Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer

  NCT00382070

  Condition:   Breast Cancer
  Interventions:   Drug: Letrozole;   Other: Placebo
  Sponsors:   NSABP Foundation Inc;   National Cancer Institute (NCI);   Novartis
  Active, not recruiting
• Olaparib and Cediranib Maleate in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial Cancer

  NCT03660826

  Conditions:   Endometrial Undifferentiated Carcinoma;   Endometrioid Adenocarcinoma;   Recurrent Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma;   Stage IV Uterine Corpus Cancer AJCC v7;   Stage IVA Uterine Corpus Cancer AJCC v7;   Stage IVB Uterine Corpus Cancer AJCC v7
  Interventions:   Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Evaluation of Mammographic Breast Density in Participants With Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502

  NCT03609021

  Conditions:   Breast Carcinoma;   Estrogen Receptor Negative;   Progesterone Receptor Negative
  Interventions:   Procedure: Screening Mammography;   Procedure: Biospecimen Collection
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.

  NCT00245739

  Condition:   HIV Infections
  Intervention:   Drug: TMC-114
  Sponsor:   Tibotec Pharmaceuticals, Ireland
  Approved for marketing
• Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

  NCT00217737

  Conditions:   Colon Mucinous Adenocarcinoma;   Colon Signet Ring Cell Adenocarcinoma;   Lynch Syndrome;   Stage IIA Colon Cancer AJCC v7;   Stage IIB Colon Cancer AJCC v7;   Stage IIC Colon Cancer AJCC v7
  Interventions:   Biological: Bevacizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease

  NCT00134173

  Conditions:   Coronary Disease;   Coronary Arteriosclerosis;   Hyperlipidemia
  Interventions:   Drug: torcetrapib/atorvastatin;   Drug: atorvastatin
  Sponsor:   Pfizer
  Completed
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

  NCT03155997

  Condition:   Breast Cancer
  Interventions:   Drug: Abemaciclib;   Drug: Standard Adjuvant Endocrine Therapy
  Sponsors:   Eli Lilly and Company;   NSABP Foundation Inc
  Active, not recruiting
• Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

  NCT03067181

  Conditions:   Adult Germ Cell Tumor;   Childhood Extracranial Germ Cell Tumor;   Childhood Germ Cell Tumor;   Extragonadal Embryonal Carcinoma;   Grade 2 Immature Ovarian Teratoma;   Grade 3 Immature Ovarian Teratoma;   Malignant Germ Cell Tumor;   Stage I Ovarian Choriocarcinoma;   Stage I Ovarian Embryonal Carcinoma;   Stage I Ovarian Teratoma;   Stage I Ovarian Yolk Sac Tumor;   Stage I Testicular Choriocarcinoma AJCC v6 and v7;   Stage I Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage I Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage II Ovarian Choriocarcinoma;   Stage II Ovarian Embryonal Carcinoma;   Stage II Ovarian Yolk Sac Tumor;   Stage II Testicular Choriocarcinoma AJCC v6 and v7;   Stage II Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage II Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage III Ovarian Choriocarcinoma;   Stage III Ovarian Embryonal Carcinoma;   Stage III Ovarian Yolk Sac Tumor;   Stage III Testicular Choriocarcinoma AJCC v6 and v7;   Stage III Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage III Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage IV Ovarian Choriocarcinoma;   Stage IV Ovarian Embryonal Carcinoma;   Stage IV Ovarian Yolk Sac Tumor;   Testicular Mixed Choriocarcinoma and Embryonal Carcinoma;   Testicular Mixed Choriocarcinoma and Teratoma;   Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
  Interventions:   Other: Best Practice;   Drug: Bleomycin;   Biological: Bleomycin Sulfate;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS

  NCT02926911

  Conditions:   DCIS;   Ductal Carcinoma in Situ
  Interventions:   Other: Guideline Concordant Care;   Other: Active Surveillance
  Sponsors:   Alliance Foundation Trials, LLC.;   Patient-Centered Outcomes Research Institute;   Duke University;   Dana-Farber Cancer Institute;   M.D. Anderson Cancer Center;   New York University;   Washington University School of Medicine
  Recruiting
• Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension

  NCT02867813

  Condition:   Dyslipidemia
  Intervention:   Biological: Evolocumab
  Sponsor:   Amgen
  Active, not recruiting
• Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT02839707

  Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Undifferentiated Carcinoma;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Undifferentiated Carcinoma;   Platinum-Resistant Ovarian Carcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
  Interventions:   Drug: Atezolizumab;   Biological: Bevacizumab;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Quality-of-Life Assessment
  Sponsor:   National Cancer Institute (NCI)
  Suspended
• Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer

  NCT02839343

  Conditions:   Pancreatic Adenocarcinoma;   Borderline Resectable Adenocarcinoma of the Head of the Pancrease
  Interventions:   Radiation: radiation therapy;   Procedure: surgery;   Drug: mFOLFIRINOX;   Drug: FOLFOX
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Sky Foundation
  Active, not recruiting
• A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

  NCT02684006

  Condition:   Renal Cell Cancer
  Interventions:   Drug: Avelumab (MSB0010718C);   Drug: Axitinib (AG-013736);   Drug: Sunitinib
  Sponsor:   Pfizer
  Active, not recruiting
• informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia

  NCT02582879

  Condition:   Chronic Lymphocytic Leukemia (CLL)
  Intervention:  
  Sponsors:   Pharmacyclics LLC.;   Janssen, LP
  Recruiting
• S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

  NCT02562716

  Conditions:   Pancreatic Adenocarcinoma;   Resectable Pancreatic Carcinoma
  Interventions:   Drug: Fluorouracil;   Drug: Gemcitabine Hydrochloride;   Drug: Irinotecan Hydrochloride;   Drug: Oxaliplatin;   Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation;   Procedure: Pancreatectomy
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

  NCT02525939

  Condition:   Acute Coronary Syndrome
  Interventions:   Drug: dalcetrapib;   Drug: Placebo
  Sponsors:   DalCor Pharmaceuticals;   The Montreal Health Innovations Coordinating Center (MHICC);   Medpace, Inc.;   Roche Molecular Systems, Inc
  Active, not recruiting
• Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer

  NCT00024102

  Condition:   Breast Cancer
  Interventions:   Drug: Standard Treatment;   Drug: capecitabine
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   NCIC Clinical Trials Group
  Completed
• Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone

  NCT02516423

  Condition:   Solitary Osseous Plasmacytoma
  Interventions:   Drug: ixazomib;   Drug: lenalidomide;   Drug: dexamethasone;   Drug: zoledronic acid
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Millennium Pharmaceuticals, Inc.;   Biologics, Inc.
  Active, not recruiting
• Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  NCT02502266

  Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fallopian Tube Undifferentiated Carcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Ovarian Undifferentiated Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
  Interventions:   Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Questionnaire Administration;   Drug: Topotecan Hydrochloride
  Sponsor:   National Cancer Institute (NCI)
  Recruiting